Lucitanib
Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively[1][2][3].
Product Specifications
CAS Number
1058137-23-7
Product Name Alternative
E-3810
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
FGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/e-3810.html
Purity
98.94
Solubility
DMSO : ≥ 20.83 mg/mL
Smiles
O=C(NC)C1=CC=CC2=C1C=CC(OC3=CC=NC4=CC(OCC5(N)CC5)=C(OC)C=C43)=C2
Molecular Formula
C26H25N3O4
Molecular Weight
443.49
Precautions
H315, H319, H320
References & Citations
[1]Bello E, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71 (4) :1396-405.|[2]Colzani M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics. 2014 Jun;13 (6) :1495-509.|[3]Bello E, et al. The tyrosine kinase inhibitor E-3810 combined with NSC 125973 inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther. 2013 Feb;12 (2) :131-40
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC473604-100 1x 100 µL
CD79b (B-Cell Marker) (rIGB/1842), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
